top of page

Search Results

Results found for "positive allosteric modulators"

  • 📰 GPCR Weekly News, July 1 to 7, 2024

    for their investigation on Modulation of contextual fear acquisition and extinction by acute and chronic internalization of cognate GPCRs and disrupt downstream intracellular signaling Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders GPCRs in Cardiology, Endocrinology Neuroscience Neuron specific quantitation of Gαolf expression and signaling in murine brain tissue Modulation cortex Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism in rats: Modulation

  • 📰 GPCR Weekly News, April 1 to 7, 2024

    Brake for Airway Smooth Muscle Cell Movement Hepatic extracellular ATP/adenosine dynamics in zebrafish models Chemoattractant receptor signaling in humoral immunity Industry News Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders Aelis Farma Reports Its 2023 Annual Financial Resultsand

  • Helix 8 in chemotactic receptors of the complement system

    Orthosteric and allosteric antagonists of C5aR1 are a novel strategy for anti-inflammatory therapies.

  • Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases

    We then highlight the evidence supporting the use of various drugs including orthosteric and allosteric

  • A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.

    and has synergistic effects with anticancer agents.[1–3] These insights highlight the potential in modulating New scaffolds modulating the CBRs in both the orthosteric and allosteric sites have been developed, supported by resolved crystal structures of both CBRs.[4–8] A key challenge in CBR modulator development is separating Translational Potential of Allosteric Modulators Targeting the Cannabinoid CB1 Receptor. Identification of the First Synthetic Allosteric Modulator of the CB2 Receptors and Evidence of Its Efficacy

  • Structural basis for receptor selectivity and inverse agonism in S1P5 receptors

    The structure demonstrates a unique ligand-binding mode, involving an allosteric sub-pocket, which clarifies

  • 📰 GPCR Weekly News, April 3 to 9, 2023

    SUCNR1 signaling in adipocytes controls energy metabolism by modulating circadian clock and leptin expression Sodium is a negative allosteric regulator of the ghrelin receptor. October 25 - 27, 2023) GPCR Jobs Convergent Research - Senior Scientist, Cell-Based Assay Development Post in protein production Vice President, Oncology Clinical Research PostDoctoral Associate PostDoctoral Position Team Lead protein production and profiling Pharmacologist Postdoctoral positions at UC San Diego Medical

  • Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery

    form biologically active homodimers or heterodimers which drive specific signaling pathways that can modulate highlight the importance of GPCR dimers in drug discovery referring to important conformational changes, allosteric al. recently provided key insights into GPCR oligomerization and biased signalling, using PAFR as a model Different models of dimer formation have been described for different receptors such as the ‘rolling dimer’ interface model in which multiple dimer conformations co-exist and interconvert (P.M.

  • 📰 GPCR Weekly News, July 24 to July 30, 2023

    GPCR Symposium on GPCRs as Therapeutic Modalities is on September 22nd. GPCR Activation and Signaling Endosome positioning coordinates spatially selective GPCR signaling. Structural and Molecular Insights into GPCR Function Ternary model structural complex of C5a, C5aR2, Target (September 25 - 28, 2023) ○ NEW Training Seminar "The Renaissance in GPCRs as Drug Targets: Allosteric

  • Chemokine receptor-targeted drug discovery: progress and challenges

    There are only two drugs in the market targeting chemokine receptors: maraviroc, an allosteric and reversible receptors can homo- and hetero-oligomerize, impacting receptor/ligand-binding and signaling patterns, by modulating These larger interfaces represent the typical protein-protein interactions which are difficult to modulate Overall, the future potential lies in using different therapeutic modalities to modulate the stromal

  • 📰 GPCR Weekly News, June 17 to 23, 2024

    failure drug following reverse merger with Avrobio Addex Pharma unveils new mGlu7 receptor negative allosteric modulators Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic in Epilepsy Models Biophysicists decipher functionality of adrenaline-binding receptor Tectonic plates Basic and Clinical Pharmacology 2026 GPCR Jobs HIGHLIGHT Principal Scientist, In vitro pharmacology NEW Post-Doctoral Pharmacology Postdoctoral Scientist Senior Research Associate/Associate Scientist, Protein Science Post-Doctoral

  • 📰 GPCR Weekly News, April 10 to 16, 2023

    Now you can submit your job opening and offer a position in an exclusive GPCR community around the globe Reviews, GPCRs, and more Internal and external modulation factors of the orexin system (REVIEW). Industry News A Current View of Allosteric GPCR Drug Discovery from the 2nd Annual GPCRs-Targeted Drug NEW Scientist—Immuno-Oncology Convergent Research - Senior Scientist, Cell-Based Assay Development Post in protein production Vice President, Oncology Clinical Research PostDoctoral Associate PostDoctoral Position

  • Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls

    The midpoint and maximum—core parameters for downstream modeling—are only meaningful when the assay fully Unexpected outcomes typically trace back to a single issue: transferring assumptions from idealized models This frequently masquerades as: Two binding sites Multiple receptor subtypes Allosteric modulation But

  • 📰 GPCR Weekly News, March 25 to March 31, 2024

    effects on mouse metabolism Mechanistic insights into sodium ion-mediated ligand binding affinity and modulation analysis Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism in rats: Modulation Excellence Awards Domain Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology Crinetics Pharmaceuticals gets grant for patent granted for somatostatin modulators for treating hormone-related conditions Sosei Heptares Confirms Re-election of its Board

  • 📰 GPCR Weekly News, May 8 to 14, 2023

    An allosteric modulator of the adenosine A1 receptor potentiates the antilipolytic effect in rat adipose Molecule Created Through Generative AI Platform to Enter Clinical Stage X4 Pharmaceuticals Announces Positive

  • ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the...

    October 2022 ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the incretin polypeptide GIP "Attention deficit/hyperactivity disorder (ADHD) is the most common childhood neurodevelopmental disorder. Single nucleotide polymorphisms (SNPs) in the Adhesion G Protein-Coupled Receptor L3 (ADGRL3) gene are associated with increased susceptibility to developing ADHD worldwide. However, the effect of ADGRL3 non-synonymous SNPs (nsSNPs) on the ADGRL3 protein function is vastly unknown. Using several bioinformatics tools to evaluate the impact of mutations, we found that nsSNPs rs35106420, rs61747658, and rs734644, previously reported to be associated and in linkage with ADHD in disparate populations from the world over, are predicted as pathogenic variants. Docking analysis of rs35106420, harbored in the ADGLR3-hormone receptor domain (HRM, a common extracellular domain of the secretin-like GPCRs family), showed that HRM interacts with the Glucose-dependent insulinotropic polypeptide (GIP), part of the incretin hormones family. GIP has been linked to the pathogenesis of diabetes mellitus, and our analyses suggest a potential link to ADHD. Overall, the comprehensive application of bioinformatics tools showed that functional mutations in the ADGLR3 gene disrupt the standard and wild ADGRL3 structure, most likely affecting its metabolic regulation. Further in vitro experiments are granted to evaluate these in silico predictions of the ADGRL3-GIP interaction and dissect the complexity underlying the development of ADHD." Read more at the source #DrGPCR #GPCR #IndustryNews

  • Cholesterol occupies the lipid translocation pathway to block phospholipid scrambling by a GPCR

    Our previous Markov State Model (MSM) analysis of molecular dynamics simulations of membrane-embedded

  • 📰 GPCR Weekly News, April 24 to 30, 2023

    GPCR Binders, Drugs, and more Allosteric modulation of a human odorant receptor. assays allow the analysis of binding kinetics of WNT-3A to endogenous Frizzled 7 in a colorectal cancer model

  • 📰 GPCR Weekly News, November 13 to 19, 2023

    ubiquitin ligase adaptor for substrate linear polyubiquitination GPCR Binders, Drugs, and more Dual allosteric to a high salt challenge in the Dahl SS rat GPCRs in Neuroscience Neurokinin-2 receptor negatively modulates Meiling Lim TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive Fellow NEW Research Associate I, Tissue Culture Post-Doc Research Associate Postdoctoral Fellow Research Scientist/Postdoctoral Associate in Computational Chemistry/Biophysics Post-Doctoral Associate Team

  • Pharmacophore-guided Virtual Screening to Identify New β 3 -adrenergic Receptor Agonists

    Previous pharmacophore modeling studies of the β3 -AR did not involve experimental in vitro validation Ligand-based pharmacophore modeling was performed since no 3D structure of human β3 -AR is yet available A dataset consisting of β3 -AR agonists was prepared to build and validate the pharmacophore models. The best model was employed for prospective virtual screening, followed by physicochemical property filtering

  • 📰 GPCR Weekly News, August 14 to 20, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Target - DOT (September 25 - 28, 2023) Training Seminar "The Renaissance in GPCRs as Drug Targets: Allosteric Interactions of GPCRs, Ion Channels, and Transport Proteins (March 24 - 29, 2024) GPCR Jobs NEW PhD Student Position

  • 📰 GPCR Weekly News, August 7 to 13, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Want to share your project in a casual way? Target - DOT (September 25 - 28, 2023) Training Seminar "The Renaissance in GPCRs as Drug Targets: Allosteric

  • 📰 GPCR Weekly News, September 18 to 24, 2023

    GPCR Symposium about 'GPCRs as Therapeutic Modalities' rocked it! Binders, Drugs, and more An inverse agonist of orphan receptor GPR61 acts by a G protein-competitive allosteric functional survival of human islets AT2 receptor agonist LP2 restores respiratory function in a rat model Clinical Research NEW Scientist (level I or II) NEW Research Fellow Research Technician II - Surgery Post-Doc

  • 📰 GPCR Weekly News, December 18 to 31, 2023

    We’ve curated 23 GPCR papers, four industry news, and 3 GPCR job posts! This week's highlight: Drs. Tribolium castaneum GPCR Activation and Signaling Palmitoylation of the Glucagon-like Peptide-1 Receptor Modulates Measure Receptor-Ligand Interactions How accurately can one predict drug binding modes using AlphaFold models duplications linked to phloem feeding Structural and Molecular Insights into GPCR Function Studying allosteric Associate Scientist Postdoctoral Scholar - O’Neill Lab Junior Research Scientist Postdoctoral Fellow Post-Doc

  • 📰 GPCR Weekly News, December 4 to 10, 2023

    course covers fundamental pharmacology in four weekly segments, delving into Agonists, Antagonists, and Allosteric Modulators.  | 20th World Congress of Basic and Clinical Pharmacology 2026 GPCR Jobs NEW Postdoctoral Fellow NEW Post-Doc

  • 📰 GPCR Weekly News, February 13 to 19, 2023

    Mandibulofacial dysostosis with alopecia results from ETAR gain-of-function mutations via allosteric Structural and Molecular Insights into GPCR Function Quantitative analysis of sterol-modulated monomer-dimer Protein Biochemistry) Speculative Applications (Mass Spectrometry) Speculative Applications (Chemistry) Post-Doctoral

  • Rescue of Cell Surface Expression and Signaling of Mutant Follicle-Stimulating Hormone Receptors

    previously demonstrated rescue of cell surface expression of luteinizing hormone receptor mutants by an allosteric

  • 📰 GPCR Weekly News, May 29 to June 4, 2023

    This week, we would like to highlight two new publications: Pharmacological hallmarks of allostery at GPCRs in Neuroscience DRD1 signaling modulates TrkB turnover and BDNF sensitivity in direct pathway striatal Structure-based pharmacophore modeling 1. Automated random pharmacophore model generation. Structural and Molecular Insights into GPCR Function Pharmacological hallmarks of allostery at the M4 November 2 - 4, 2023) GPCR Jobs NEW Senior Vice President of Global Medical Affairs NEW Postdoctoral Position

  • 📰 GPCR Weekly News, July 17 to July 23, 2023

    GPCR Symposium on GPCRs as Therapeutic Modalities on September 22nd. Updates in GPCR Research Fluorescent Ligands Enable Target Engagement Studies for the Intracellular Allosteric

  • Harnessing Deep Mutational Scanning for Enhanced Drug Discovery

    This high-resolution mapping can confirm the protein’s role in disease pathology and highlight allosteric The choice of model systems, such as yeast, bacteria, or mammalian cells, can heavily influence the method's Certain systems might not replicate the natural environment or post-translational modifications observed Additionally, combining DMS with computational modelling and machine learning algorithms promises to

bottom of page